Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax at Blau Farmaceutica S.A. Laboratory in Relation to Drug Eprex, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease.

Trial Profile

Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax at Blau Farmaceutica S.A. Laboratory in Relation to Drug Eprex, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.
    • 06 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top